AzTrials
AzTrials

Venous ThromboembolismPhase 1DEEPNCT01014403

Delayed Versus Early Enoxaparin Prophylaxis After Traumatic Brain Injury (TBI)

A Phase 1 study testing enoxaparin in people with Venous Thromboembolism and Traumatic Brain Injury, run by University of Texas Southwestern Medical Center at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Brain injured patients are at high risk for forming blood clots in the legs and lungs. For non-brain injured trauma patients, we decrease the chances of these blood clots forming by placing the patients on a low dose of the blood thinner enoxaparin. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
enoxaparin
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
62 participants
Where
2 sitesUnited States
Study dates
Nov 2009to May 2011
Phase
Phase 1
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 1. Male and female patients admitted to the ETMC SICU with TBI who speak English or Spanish.

Who cannot join

  • Epidural or subdural hematoma > 8mm.
  • Intraparenchymal contusion >2 cm
  • Multiple contusions w/in one lobe
  • Subarachnoid hemorrhage in basilar or supracellar cistern and positive CTA
  • Increased TBI on 24 hr post-injury CT
  • Spinal canal hematoma
Show all 23Show fewer
  • Nonoperative mgmt of American Association for the Surgery of Trauma (AAST) Grade IV or higher organ injury
  • Gastrointestinal hemorrhage
  • Ongoing bleeding from a pelvic fracture
  • Anticipated open reduction of long bone or pelvic fracture within study period.
  • Intracranial pressure (ICP) >20 mmHg
  • Coagulopathy consisting of International Normalized Ratio (INR)>1.5 or platelet count <50,000
  • Expect brain death/discharge in 48 hrs
  • Pre-existing dialysis dependence
  • Documented DVT at time of admission
  • Prisoners
  • Pregnancy
  • Age <18 years
  • Terminally ill patients
  • Anticoagulant use at time of injury
  • Inability to gain consent from patient or legal next-of-kin in instance of TBI, intoxication, or psychiatric diagnoses
  • Documented history of heparin allergy
  • Initial head CT >6 hours post-injury

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • UT-Southwestern Medical Center

    Dallas, Texas, 75390

  • East Texas Medical Center

    Tyler, Texas, 75701

Other trials in United States

About this study

Official title: The Delayed vs Early Enoxaparin Prophylaxis (DEEP) Study After Traumatic Brain Injury: A Randomized, Double-Blinded, Placebo Controlled Pilot Trial

Brain injured patients are at high risk for forming blood clots in the legs and lungs. For non-brain injured trauma patients, we decrease the chances of these blood clots forming by placing the patients on a low dose of the blood thinner enoxaparin. Starting patients with a brain injury on the blood thinner is problematic, however, as this can theoretically cause the brain injury to worsen. Trauma surgeons wait a variable period of time before starting this blood thinner because waiting too long can result in the formation of these blood clots in the legs and lungs. Previous research has shown that some brain injuries which are of lower severity can have enoxaparin started at 24 hours after injury if the brain injury is stable on a repeated computed tomography (CT) scan of the head. This is a pilot study designed to look at the rates of worsening of brain injury if the low dose blood thinner is started at 24 versus 96 hours post-injury.

Read the detailed description

We propose to conduct a placebo-controlled non-inferiority pilot study to evaluate the rate of worsening of intracranial injury patterns after initiation of enoxaparin in TBI patients. Patient enrollment will occur at ETMC, blinded re-reading of CTs will occur at PMH, and administrative/analytical support will occur at UTSW. The study design will be a double-blind, randomized controlled trial in the ETMC Surgical Intensive Care Unit (SICU) consisting of 40 patients per arm. The decision for 80 patients was resource-based, as this is a pilot study. Further, we anticipate the need to contact 3 patients in order to obtain 1 successful recruitment.

Each arm will consist of low-risk TBI patients (defined as patients with a subdural or epidural hematoma < 8mm, intraparenchymal contusion < 2 cm, and/or single contusion per lobe) who have had a CT scan of the head without contrast at 24 hours post-injury which documents a stable injury pattern. The severity of neurologic deficit will have no bearing on their suitability for participation, and will not be considered in inclusion/exclusion criteria. After documentation of a stable intracranial injury pattern at this time interval, patients will be randomized to receive either enoxaparin 30 mg SQ every 12 hours or placebo with each regimen being initiated at 24 hours post-injury. A follow-up CT scan of the brain without contrast will be obtained on all patients 48 hours post-injury (and 24 hours after the initiation of enoxaparin/placebo). An additional CT scan of the brain without contrast will be obtained on any patient who experiences an abrupt change in neurologic exam at any time between the initiation of enoxaparin/placebo and the end of the study's interventional period at 96 hours post-injury (this time frame was chosen as it is the earliest time point at which there is universal agreement among both of our group's practitioners that enoxaparin use is safe from the risks of TBI expansion). Any patient with a worsened CT scan will have their investigational treatment discontinued at that time. At 96 hours post-injury, the interventional portion of the study will end, data collection for the primary endpoint will cease, and all patients will be placed on enoxaparin for the remainder of their hospital stay as per local standards of care. Patient participation in the study will last from the time of injury to 96 hours post-injury for the interventional part of the study, and from 96 hours post-injury until discharge from ETMC for the observational portion. While this latter time frame is obviously extremely variable, it averages approximately one to two weeks. During both the interventional and observational time periods, patients will have Duplex ultrasonography of the lower extremities performed for an edematous extremity, CT-angiography of the chest for unexplained hypoxia or tachycardia, and ventilation-perfusion scanning for suspicion of PE in the presence of a contraindication to IV contrast.

Being tested
enoxaparin, placebo
Keywords
venous thromboembolism, enoxaparin, traumatic brain injury, Venous thromboembolism prophylaxis traumatic brain injury
Medical subject headings
Venous Thromboembolism, Brain Injuries, Traumatic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • enoxaparinDrug

    Enoxaparin 30 mg sq q 12 hours

  • placeboDrug

    vehicle

Study groups in NCT01014403
Study groupRoleWhat they receive
enoxaparin 30 mg SQ q12 hoursExperimentalEnoxaparin started at 24 hours post-injury and continued until 96 hours post-injury.
Receives: Drug: enoxaparin
placeboPlacebo comparatorvehicle administered sq q 12 hours
Receives: Drug: placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With Worsening TBI Hemorrhage

    Worsening of TBI hemorrhage pattern on any scheduled or PRN CT scans after the initiation of treatment

    Measured: 24 hours after the start of treatment/48 hours after the time of injury

Secondary outcomes (2)
  1. Extracranial Hemorrhagic Complications

    percentage of participants that have extracranial hemorrhagic complications

    Measured: prior to discharge

  2. Count of Participants With Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)

    Measured: prior to discharge

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Nov 2009 (estimated)
  2. Study startNov 2009
  3. Primary completionMay 2011
  4. Study completionMay 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
62 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01014403
Sponsor's protocol ID
082009-026
Acronym
DEEP
Status last verified
Dec 2020
First submitted
13 Nov 2009
Last updated
13 Jan 2021
Data monitoring committee
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing enoxaparin in people with Venous Thromboembolism and Traumatic Brain Injury, run by University of Texas Southwestern Medical Center at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 13 Jan 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With Worsening TBI Hemorrhage (time frame: 24 hours after the start of treatment/48 hours after the time of injury). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in